Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Revenue
Annual & quarterly revenue history · segment & region breakdown
APLS · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsApellis Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $1.11B, an increase of 28.46% year-over-year from $1.00B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $1.00B | +$0.22B | +28.46% |
| 2024-12-31 | $0.78B | +$0.38B | +97.02% |
| 2023-12-31 | $0.40B | +$0.32B | +425.83% |
| 2022-12-31 | $0.08B | +$0.01B | +13.31% |
| 2021-12-31 | $0.07B | -$0.18B | -73.44% |
| 2020-12-31 | $0.25B | +$0.25B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare APLS revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Apellis Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Apellis Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Apellis Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
APLS revenue · 4 questionsAPLS's trailing twelve-month (TTM) revenue is $1.11B. That is an increase of 28.46% year-over-year from $1.00B in FY2025.
▸ Source: FMP · Apellis Pharmaceuticals, Inc. SEC filings · GAAP · Apellis Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026